ID
42476
Descripción
Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. Please note that only cases with known outcome are collected! Baseline / diagnosis is defined as the day the sample of the first positive SARS-CoV-2 result was taken. Criteria of the Uncomplicated Phase: Asymptomatic OR Symptoms of upper respiratory tract infection and/or Nausea, emesis, diarrhea and/or Fever Remember: The Uncomplicated Phase ends, if a previously febrile patient has no fever anymore and has completed 14 days of follow-up without entering Complicated or Critical Phase; then move to Recovery Phase. Also, as soon as one of the criteria of the Complicated or Critical Phase are fulfilled, Uncomplicated Phase ends; move over to there. If the patient has died, the phase ends with the death of the patient. If the patient has died, do not report terminal values, e.g. those recorded after switching off life-support or heart rate "0" after death of the patient. Criteria of the Complicated Phase: * Need for oxygen supplementation (In patients with prior oxygen home therapy, clinically meaningful increase in need for oxygenation.) * paO2 at room air < 70 mmHg * SO2 at room air < 90 % * GOT or GPT > 5x ULN * New cardiac arrhythmia * New pericardial effusion >1cm * New heart failure with pulmonary edema, congestive hepatopathy or peripheral edema Remember: The Complicated Phase ends, if none of the criteria for the Complicated Phase is fulfilled anymore AND the patient is free of fever; then move to Recovery Phase. Also, as soon as one of the criteria of the Critical Phase are fulfilled, Complicated Phase ends; move over to Critical Phase. If the patient has died, the phase ends with the death of the patient. If the patient has died, do not report terminal values, e.g. those recorded after switching off life-support or heart rate "0" after death of the patient. Criteria of the Critical Phase: * Need for catecholamines * Life-threatening cardiac arrhythmia * Mechanical ventilation (invasive or non-invasive) * Liver failure with Quick< 50% * qSOFA >= 2 * Renal failure in need of dialysis Remember: The Critical Phase ends as soon as none of the criteria for the Critical Phase is fulfilled anymore AND the patient is free of fever. If the patient has died, it ends with the death of the patient. If the patient has died, do not report terminal values, i.e. those recorded after turning off life-support or heart rate "0" after death of the patient. Criteria of the Recovery Phase: *Improvement by at least one phase, i.e. Critical to Complicated or Complicated to Uncomplicated * Defervescence Remember: Uncomplicated asymptomatic patients enter recovery phase after 14 days of observation without disease progression No further progression or re-hospitalization If a text field can't be filled out, note 'ND' (for not determined).
Link
Palabras clave
Versiones (3)
- 2/7/21 2/7/21 - Sarah Riepenhausen
- 15/7/21 15/7/21 - Sarah Riepenhausen
- 16/7/21 16/7/21 - Sarah Riepenhausen
Titular de derechos de autor
LEOSS
Subido en
16 de julio de 2021
DOI
10.21961/mdm:42476
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients
Immunosuppressive premedication
- StudyEvent: Baseline
- StudyEvent: Comorbidities and Pre-medication
- StudyEvent: Phases
- StudyEvent: Therapeutics
- StudyEvent: Diagnostics
Descripción
Antibodies: CD-22
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C0054947
Descripción
Antibodies: CD-38
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C0075742
Descripción
Antibodies: CD-52
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C1610534
Descripción
Antibodies: Anti-CD79b
Alias
- UMLS CUI-1
- C0104979
- UMLS CUI-2
- C0003241
Descripción
Antibodies: B Lymphocyte stimulator-specific inhibitor (BLyS)
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C3160093
Descripción
Antibodies: CD19-BiTE
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C4727095
Descripción
Antibodies: Complement inhibitors
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C1564892
Descripción
Crovalimab
Tipo de datos
integer
Alias
- UMLS CUI [1,1]
- C1564892
- UMLS CUI [1,2]
- C3846158
Descripción
Eculizumab
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C1541483
Descripción
Pegcetacoplan (APL-2)
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C4053680
Descripción
Ravulizumab
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C4550350
Descripción
Antibodies: Integrin antagonists
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C2917367
Descripción
Antibodies: Interleukin inhibitors
Alias
- UMLS CUI-1
- C3653320
- UMLS CUI-2
- C0003241
Descripción
Basiliximab
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C0676831
Descripción
Canakinumab
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C2718773
Descripción
Ixekizumab
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C3489764
Descripción
Sarilumab
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C3885145
Descripción
Secukinumab
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C3179547
Descripción
Tocilizumab
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C1609165
Descripción
Ustekinumab
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C1608841
Descripción
Antibodies: TNF-alpha inhibitors
Alias
- UMLS CUI-1
- C3653350
- UMLS CUI-2
- C0003241
Descripción
Adalimumab
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C1122087
Descripción
Certolizumab
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C1872109
Descripción
Etanercept
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C0717758
Descripción
Golimumab
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C2353893
Descripción
Infliximab
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C0666743
Descripción
Other Antibodies
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C0205394
Descripción
Inhibitors: Co-stimulation inhibitors
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C1622572
- UMLS CUI-3
- C1999216
Descripción
Inhibitors: Calcineurin inhibitors
Alias
- UMLS CUI-1
- C1562036
Descripción
Inhibitors: Interleukin inhibitor
Alias
- UMLS CUI-1
- C3653320
Descripción
Inhibitors: JAK inhibitors
Alias
- UMLS CUI-1
- C3854325
Descripción
Baricitinib
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C4044947
Descripción
Fedratinib
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C3886623
Descripción
Ruxolitinib
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C2931926
Descripción
Tofacitinib
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C2930696
Descripción
Upadacitinib
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C4726929
Descripción
Inhibitors: mTOR inhibitors
Alias
- UMLS CUI-1
- C2746052
Descripción
Inhibitor: PDE-4-inhibitor
Alias
- UMLS CUI-1
- C2936609
Descripción
Other Inhibitors
Alias
- UMLS CUI-1
- C0205394
- UMLS CUI-2
- C0243077
Descripción
Checkpoint inhibitors: last 3 months
Alias
- UMLS CUI-1
- C0332185
- UMLS CUI-2
- C4733472
Descripción
In case of combination therapy please indicate all of the respective drugs.
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C3657270
Descripción
In case of combination therapy please indicate all of the respective drugs.
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C3658706
Descripción
In case of combination therapy please indicate all of the respective drugs.
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C1367202
Descripción
In case of combination therapy please indicate all of the respective drugs.
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C0205394
- UMLS CUI [1,3]
- C4733472
Descripción
Indicate recent other checkpoint inhibitor
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C0205394
- UMLS CUI [1,3]
- C4733472
- UMLS CUI [1,4]
- C1521902
Descripción
No recent checkpoint inhibitor therapy
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C1298908
- UMLS CUI [1,2]
- C0332185
- UMLS CUI [1,3]
- C4733472
Descripción
Unknown Checkpoint inhibitor therapy
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0439673
- UMLS CUI [1,2]
- C0332185
- UMLS CUI [1,3]
- C4733472
Descripción
Chemotherapeutics: Antimetabolites
Alias
- UMLS CUI-1
- C0003376
- UMLS CUI-2
- C0729502
Descripción
6-Mercaptopurine
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C0000618
Descripción
Azathioprine
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C0004482
Descripción
Leflunomide
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C0063041
Descripción
Methotrexate
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C0025677
Descripción
Mycophenolate mofetil / Mycophenolic acid
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C0209368
- UMLS CUI [2]
- C0026933
Descripción
Sulfasalazine
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C0036078
Descripción
Teriflunomide
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C1718383
Descripción
Chemotherapeutics: Cytostatics
Alias
- UMLS CUI-1
- C0010858
- UMLS CUI-2
- C0729502
Descripción
Recent: Cladribine (2-CDA) i.v./s.c.
Tipo de datos
integer
Alias
- UMLS CUI [1,1]
- C0092801
- UMLS CUI [1,2]
- C0348016
- UMLS CUI [1,3]
- C0332185
- UMLS CUI [2,1]
- C0092801
- UMLS CUI [2,2]
- C0021499
- UMLS CUI [2,3]
- C0332185
Descripción
Recent: Cladribine (2-CDA) p.o.
Tipo de datos
integer
Alias
- UMLS CUI [1,1]
- C0092801
- UMLS CUI [1,2]
- C0001563
- UMLS CUI [1,3]
- C0332185
Descripción
Recent: Cyclophosphamide i.v.
Tipo de datos
integer
Alias
- UMLS CUI [1,1]
- C0010583
- UMLS CUI [1,2]
- C0348016
- UMLS CUI [1,3]
- C0332185
Descripción
Recent: Cyclophosphamide p.o.
Tipo de datos
integer
Alias
- UMLS CUI [1,1]
- C0010583
- UMLS CUI [1,2]
- C0001563
- UMLS CUI [1,3]
- C0332185
Descripción
Recent: Mitoxantrone
Tipo de datos
integer
Alias
- UMLS CUI [1,1]
- C0026259
- UMLS CUI [1,2]
- C0332185
Descripción
Other Chemotherapeutics
Alias
- UMLS CUI-1
- C0205394
- UMLS CUI-2
- C0729502
Descripción
Other Chemotherapeutics
Tipo de datos
integer
Alias
- UMLS CUI [1,1]
- C0205394
- UMLS CUI [1,2]
- C0729502
Descripción
Indicate other Chemotherapeutics
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C0729502
- UMLS CUI [1,2]
- C0205394
- UMLS CUI [1,3]
- C1521902
Descripción
Other immunosuppressive regimens: Corticosteroids
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C0001617
Descripción
low dose prednisolone equivalent
Tipo de datos
integer
Alias
- UMLS CUI [1,1]
- C0445550
- UMLS CUI [1,2]
- C0038317
Descripción
medium dose prednisolone equivalent
Tipo de datos
integer
Alias
- UMLS CUI [1,1]
- C0439536
- UMLS CUI [1,2]
- C0178602
- UMLS CUI [1,3]
- C0038317
Descripción
high dose prednisolone equivalent
Tipo de datos
integer
Alias
- UMLS CUI [1,1]
- C0038317
- UMLS CUI [1,2]
- C0444956
Descripción
Other immunosuppressive regimens: Fumarate
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C0220833
Descripción
Dimethyl fumarate
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C0058218
Descripción
Dimethyl fumarate/ethyl hydrogen fumarate (Fumaderm)
Tipo de datos
integer
Alias
- UMLS CUI [1,1]
- C0058218
- UMLS CUI [1,2]
- C0059764
- UMLS CUI [2]
- C0633802
Descripción
Other immunosuppressive regimens: Immunoglobulines
Alias
- UMLS CUI-1
- C1963758
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C0021081
Descripción
Other immunosuppressive regimens: Interferon
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C3652465
Descripción
Other immunosuppressive regimens: Other Multiple Sclerosis drugs
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C0013227
- UMLS CUI-4
- C0026769
Descripción
Other immunosuppressive regimens
Alias
- UMLS CUI-1
- C0205394
- UMLS CUI-2
- C0021081
Descripción
Other immunosuppressive drugs
Tipo de datos
integer
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C0205394
Descripción
Indicate other immunosuppressive drugs
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C0205394
- UMLS CUI [1,3]
- C1521902
Descripción
Immunosuppressive drugs: Underlying disease
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C3146298
Descripción
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0026769
Descripción
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0205494
- UMLS CUI [1,4]
- C0004364
- UMLS CUI [1,5]
- C0205394
Descripción
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0205478
Descripción
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0029216
Descripción
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C3495832
Descripción
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0277554
- UMLS CUI [1,4]
- C0205394
Descripción
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0277554
- UMLS CUI [1,4]
- C0205394
- UMLS CUI [1,5]
- C1521902
Descripción
Indication for immunosuppressive drugs: Unknown underlying disease
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0439673
- UMLS CUI [1,4]
- C0277554
Descripción
Is data entry for this section finished?
Alias
- UMLS CUI-1
- C4684556
- UMLS CUI-2
- C1828479
- UMLS CUI-3
- C0205197
Similar models
Immunosuppressive premedication
- StudyEvent: Baseline
- StudyEvent: Comorbidities and Pre-medication
- StudyEvent: Phases
- StudyEvent: Therapeutics
- StudyEvent: Diagnostics
C0332185 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,2])
C0003241 (UMLS CUI-2)
C3160093 (UMLS CUI-2)
C0332185 (UMLS CUI [1,2])
C1564892 (UMLS CUI-2)
C2917367 (UMLS CUI-2)
C0003241 (UMLS CUI-2)
C0003241 (UMLS CUI-2)
C1521902 (UMLS CUI [1,2])
C0003241 (UMLS CUI [1,3])
C1622572 (UMLS CUI-2)
C1999216 (UMLS CUI-3)
C1521902 (UMLS CUI [1,2])
C0243077 (UMLS CUI [1,3])
C4733472 (UMLS CUI-2)
C3657270 (UMLS CUI [1,2])
C3658706 (UMLS CUI [1,2])
C1367202 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])
C4733472 (UMLS CUI [1,3])
C0205394 (UMLS CUI [1,2])
C4733472 (UMLS CUI [1,3])
C1521902 (UMLS CUI [1,4])
C0332185 (UMLS CUI [1,2])
C4733472 (UMLS CUI [1,3])
C0332185 (UMLS CUI [1,2])
C4733472 (UMLS CUI [1,3])
C0729502 (UMLS CUI-2)
C0026933 (UMLS CUI [2])
C0729502 (UMLS CUI-2)
C0348016 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0092801 (UMLS CUI [2,1])
C0021499 (UMLS CUI [2,2])
C0332185 (UMLS CUI [2,3])
C0001563 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0348016 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0001563 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0332185 (UMLS CUI [1,2])
C0729502 (UMLS CUI-2)
C0729502 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])
C1521902 (UMLS CUI [1,3])
C0205394 (UMLS CUI-2)
C0001617 (UMLS CUI-3)
C0038317 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,2])
C0038317 (UMLS CUI [1,3])
C0444956 (UMLS CUI [1,2])
C0205394 (UMLS CUI-2)
C0220833 (UMLS CUI-3)
C0059764 (UMLS CUI [1,2])
C0633802 (UMLS CUI [2])
C0205394 (UMLS CUI-2)
C0021081 (UMLS CUI-3)
C0348016 (UMLS CUI [1,2])
C0021499 (UMLS CUI [1,2])
C0205394 (UMLS CUI-2)
C3652465 (UMLS CUI-3)
C0205394 (UMLS CUI-2)
C0013227 (UMLS CUI-3)
C0026769 (UMLS CUI-4)
C0021081 (UMLS CUI-2)
C0205394 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])
C1521902 (UMLS CUI [1,3])
C3146298 (UMLS CUI-2)
C3146298 (UMLS CUI [1,2])
C0026769 (UMLS CUI [1,3])
C3146298 (UMLS CUI [1,2])
C0205494 (UMLS CUI [1,3])
C0004364 (UMLS CUI [1,4])
C0205394 (UMLS CUI [1,5])
C3146298 (UMLS CUI [1,2])
C0205478 (UMLS CUI [1,3])
C3146298 (UMLS CUI [1,2])
C0029216 (UMLS CUI [1,3])
C3146298 (UMLS CUI [1,2])
C3495832 (UMLS CUI [1,3])
C3146298 (UMLS CUI [1,2])
C0277554 (UMLS CUI [1,3])
C0205394 (UMLS CUI [1,4])
C3146298 (UMLS CUI [1,2])
C0277554 (UMLS CUI [1,3])
C0205394 (UMLS CUI [1,4])
C1521902 (UMLS CUI [1,5])
C3146298 (UMLS CUI [1,2])
C0439673 (UMLS CUI [1,3])
C0277554 (UMLS CUI [1,4])
C1828479 (UMLS CUI-2)
C0205197 (UMLS CUI-3)
C1828479 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])